Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. Cortese discusses the current gaps in ADHD treatment.
While the coronavirus disease 2019 (COVID-19) pandemic has forced organizers to replace bustling live conferences with virtual ones, it has also enabled a more inclusive presenter list.
Taking advantage of the ease of the situation, the organizers for last month’s American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference were able to present a slate of international attention deficit/hyperactivity disorder (ADHD) researchers.
The meeting featured posters and new data presentations from investigators across the globe, including the US, UK, Germany and Japan, who were able to log onto their computer and network with colleagues as opposed to having to fly across the globe at an expense.
One such ADHD researchers was Samuele Cortese, MD, PhD, Professor of Child and Adolescent Psychiatry, University of Southampton.
In an interview with HCPLive®, Cortese explained how important it is to bring an international class of researchers together in the virtual format to share data and discuss best practices in ADHD care.
The fact of the matter is ADHD is likely going to change in the future because of the ongoing pandemic.
Cortese discussed some of the known gaps in how clinicians treat ADHD patients and what could be done in the future to close some of these gaps.